Chirality is a key factor in the safety and efficacy of many drug products and thus the
production of single enantiomers of drug intermediates and drugs has become important …

Hepatitis C virus (HCV) infection is a major health problem worldwide. Approximately, 170-
200 million individuals are chronically infected worldwide and a quarter of these patients are …

A government‐funded interferon‐free direct‐acting antiviral (DAA) treatment programme for
chronic hepatitis C virus (HCV) infection has been available in Australia since March 2016 …

Hepatitis C virus (HCV) infection, defined by active carriage of HCV RNA, affects nearly
1.0% of the worldwide population. The main risk factors include unsafe injection drug use …

Hepatitis C virus (HCV) infection is one of the primary causes of liver cirrhosis and
hepatocellular carcinoma. In hemodialysis patients, the rate of HCV infection is high and is …

Ribavirin, once a staple of hepatitis C treatment, has significant drawbacks, including
treatment-limiting side effects, the requirement for intensive laboratory monitoring, the need …

Background and aim: Soluble CD 163 (sCD163) is released from activated liver
macrophages in chronic viral hepatitis C (HCV) and serum levels reflect liver disease …

Abstract Background & Aims Hepatitis C virus (HCV) therapies with interferon‐free second‐
generation direct‐acting antivirals (DAA s) are highly effective and well tolerated. They have …

Background and aim. Grazoprevir is an NS3/4A protease inhibitor (PI), while elbasvir is an
NS5A inhibitor. We performed this meta-analysis to directly compare grazoprevir plus …

A simple and sensitive stability indicating high performance liquid chromatography method
was developed for quantification of Daclatasvir hydrochloride in bulk and tablet dosage …